Related Experiment Videos
Clinical treatment of epilepsy with calcium entry blockers
Abstract:
In view of the known role of Ca2+ in the paroxysmal depolarisation shifts of epileptic neurons, the possibility arises that certain Ca2+ entry blockers possess antiepileptic activity. The only drug of the class which readily passes blood-brain barrier is flunarizine. This is effective in experimental models of epilepsy and produced significant seizure reduction in two trials in therapy-resistant patients. Efficacy was maintained without development of tolerance. The safety of the drug has already been established in a great number of subjects treated for a long time for other diseases. It has few and mild side effects at therapeutic blood levels.
Insights
Flunarizine, a calcium channel blocker, shows promise in treating epilepsy by reducing seizures in patients resistant to other therapies. Its ability to cross the blood-brain barrier and established safety profile make it a viable option.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Calcium ions (Ca2+) play a critical role in neuronal hyperexcitability during epileptic seizures.
- Understanding the mechanisms of epilepsy involves investigating ion channel function and neuronal depolarization shifts.
Purpose of the Study:
- To investigate the potential antiepileptic activity of calcium (Ca2+) entry blockers.
- To evaluate flunarizine, a specific calcium channel blocker, for its efficacy and safety in epilepsy treatment.
Main Methods:
- Review of existing literature on Ca2+ channel blockers and epilepsy.
- Analysis of experimental epilepsy models demonstrating flunarizine's effectiveness.
- Examination of clinical trial data from therapy-resistant epilepsy patients treated with flunarizine.
Main Results:
- Flunarizine demonstrated efficacy in experimental epilepsy models.
- Significant seizure reduction was observed in two clinical trials involving therapy-resistant patients.
- The drug's effectiveness was sustained without the development of tolerance.
- Flunarizine possesses a favorable safety profile with mild side effects at therapeutic doses.
Conclusions:
- Flunarizine exhibits significant antiepileptic activity, particularly in drug-resistant epilepsy.
- Its ability to penetrate the blood-brain barrier and established safety profile support its therapeutic potential.
- Further research may explore flunarizine as a treatment option for specific epilepsy types.